Nursing Perspective of TB Control

Satellite Conference and Live Webcast Wednesday, April 2, 2014 2:00 – 4:00 p.m. Central Time

Produced by the Alabama Department of Public Health Video Communications and Distance Learning Division

Faculty

Tammy Langlois, BSN, RN TB Nurse Consultant Division of TB Control Alabama Department of Public Health

Other Names For Tuberculosis

- TB
- Consumption
- White Plague
- Phthisis
- Scrofula
- Potts Disease



What is TB?

- An airborne disease caused by Mycobacterium Tuberculosis
- Once the leading cause of death in United States
- Preventable and curable
- One third of the world is infected
- Over 2 million die from TB each year

How is it Spread?

- Spread through the air when infectious people cough, sneeze, or speak
- Spreads easier in small closed spaces where air does not move

Probability TB Will Be Transmitted

• Infectiousness of the person with TB

-Symptoms such as cough

• Environment where exposure occurred



- Duration of exposure
- Virulence of the organism
 - -Some "bugs" are more aggressive

TB Exposure

• Exposure occurs from being in VERY CLOSE CONTACT with someone who is sick with TB

-Breathing the same air



Exposure What Happens Next?

Infection

 Healthy immune systems fight off the bacterial infection, so the person doesn't get sick. This is: Latent TB Infection (LTBI), which occurs in 90% of those infected

Exposure What Happens Next?

• Disease

 Immuno-supressed immune systems are unable to fight off the bacterial infection and so the bacteria thrive and progress to active TB disease

 This occurs in about 10% of those infected

Differences Between LTBI and TB Disease


- LTBI
 - -Positive TB skin test
 - -Normal chest X-ray
 - -No symptoms
 - -Cannot transmit to others
 - -May be treated preventively


Differences Between LTBI and TB Disease

- TB Disease
 - -Positive TB skin test
 - -Abnormal chest X-ray
 - -Has symptoms
 - -May transmit to others
 - -May be treated and cured

Common Sites of TB Disease

- Lungs (85% of the time)
- Pleura
- Central nervous system (Meningitis)
- Lymphatic system
- Genitourinary systems
- Bones and joints
- Disseminated (miliary TB)









Persons at Higher Risk for Exposure to TB

- Close contacts of persons known or suspected to have TB
- Unemployed / minority populations / foreign - born people where TB is common
- Residents and employees of high risk congregate settings

Persons at Higher Risk for Exposure to TB


 Health care workers and first responders who serve high risk clients


Conditions That Increase the Risk of Progression to TB Disease


- Recent TB infection
 - -10% within 2 years of exposure
- HIV infection
- Substance abuse
- Diabetes, silicosis, cancer of head or neck, intestinal bypass


Conditions That Increase the Risk of Progression to TB Disease

- Prolonged corticosteroid therapy
- Other immunosuppressive therapy
- Age
 - -Very young or very old









Tools For TB Diagnosis

- Bacteriology
 - -Acid Fast Bacilli (AFB) Smear
 - -PCR (rapid test) for +AFB Smear Specimens
 - -Culture (6 8 weeks)
- Chest X-ray (PA / Lat)
- Tuberculin Skin Test (TST)

Tools For TB Diagnosis

- Blood Assay for M. tuberculosis (BAMT) Bacteriology
 - -Quantiferon TB Gold
 - QFT TB Gold
 - -T Spot

Caution!

- Tuberculin Skin Test (TST) should not be the first test to diagnose disease
 - -It is the test for latent tuberculosis infection
 - -Can be used to help support that the patient was infected with TB

Testing For Contacts to TB Cases or TB Suspects

- Concentric circle method and priority model used to determine who needs testing
- T Spot is preferred or place a TST as soon as contact is identified
- 5 mm induration considered positive TST

Testing For Contacts to TB Cases or TB Suspects

• Second test (T-Spot or TST) done in 10-12 weeks (if first test negative) due to incubation period

Measuring A Positive TB Skin Test What Really Matters?

- Measure induration or raised area only
- Do not include areas of redness outside the indurated area
- Record reading using millimeters (mm)

Measuring A Positive TB Skin Test What Really Matters?

Anterior
 Forearm



Factors Impacting TST Readings: Positive Results

- >5mm = + risk factors
 - Contact, HIV/AIDS,
 Immunosuppressive therapy,
 Cancer, Renal Disease,
 Abnormal CXR, IV Drug Abuser

Factors Impacting TST Readings: Positive Results

- >10mm = + risk factors
 - Foreign born, substance abuser, congregate settings (jail / prison, nursing home), Elderly >70,
 Healthcare Workers, Low Income (homeless), Medical Conditions
 (Diabetes, Post Gastrectomy, Corticosteroid Therapy, Silicosis)

Factors Impacting TST Readings: Positive Results

- >15mm = + risk factors
 - -General population
 - With no known risk factors listed above

TB Skin Testing Using Two - Step Method

- Use two step testing for the initial skin testing of adults who will be retested periodically
- If first test is positive, consider the person infected
- If first test is negative, repeat in 1-3 weeks

TB Skin Testing Using Two - Step Method

- If second test is positive, consider the person infected
- If second test is negative, consider the person uninfected

Starting Therapy

- Initial visit / Baseline:
 - -Skilled assessment
 - -Symptom review
 - -Weight
 - -Vision screening
 - Red / green color blindness
 and acuity

Starting Therapy

- -Sputum collection
 - Daily 3 consecutive days
- -Laboratory testing
- -T Spot
 - Mailer provided by Oxford Lab
- -HIV
- -Liver Function Test (LFTs)
- -CBC

Monitoring Therapy: Sputum Samples

- Sputum smears
 - -Initial 3 specimens
 - -Ideally over 3 consecutive days
 - -Weekly for SMEAR + after 3 consecutive NEGATIVES, then
 - -Monthly until the end of therapy

Monitoring Therapy: Sputum Samples

- Sputum cultures (same as above)
 - -Monthly until the end of therapy
 - Failure to convert cultures in a timely manner is an indication to extend therapy

Monitoring Therapy: Chest X-ray

- Chest X-rays
 - -Baseline for all TB cases / patients
 - -Interim 2 3 months into therapy
 - -Closing CXR at end of therapy

Monthly Monitoring

- Monthly
 - Face-to-face skilled assessment (RN or MD)
 - Symptom review / side effects of treatment
 - -Vision screenings while on EMB
 - -Weight

Monthly Monitoring

- -Sputum collection for AFB smear and culture during treatment
- Additional laboratory testing requested by physician or as indicated by patient's medical condition

Treatment for TB: Therapy I General Principles

- Use Rifampin (R) Isoniazid (I), Pyrazinamide (P), and Ethambutol (E) together
 - These drugs are the basis of modern short - course (6 - month) therapy
- Always treat with a multiple drug regimen (RIPE)

Treatment for TB: Therapy I General Principles

- Never add a single drug to a falling regimen
- Determine the duration of therapy based on the drugs used
- Partnering with the Alabama Department of Public Health (ADPH) will facilitate directly observed therapy (DOT) for all patients

RIF (Rifampin)

- Rifampin (RIF)
 - Excellent intracellular killing of both active and quiescent organisms
 - Required to shorten therapy to <12 months</p>
 - Increasing evidence for efficacy in the latent stage

INH (Isoniazid)

- Isoniazid (INH)
 - Good killing of actively dividing organisms
 - Documented efficacy in the latent stage

PZA (Pyrazinamide)

- Pyrazinamide (PZA)
 - Good killing of actively dividing organisms in an acidic environment
 - Decreasing effect after first 2 months of therapy
 - Required to shorten therapy to 6 months

EMB (Ethambutol)

- Ethambutol (EMB)
 - -Bacteriostatic only
 - Provides extra agent in case of resistance

Diagnosing Tuberculosis

- 81% of all Alabama's cases in 2012 were confirmed by AFB culture
- Can be culture negative and still considered a clinical case
 - -19% of all Alabama's cases in 2012
- A negative TST should not deter diagnosis

Diagnosing Tuberculosis

- Delayed diagnosis occurs often, resulting in a greater chance of secondary cases
- 138 cases were reported in Alabama in 2012

Public Health Laws

- Tuberculosis is a notifiable disease
 - Healthcare workers, hospital administrators, correctional facilities, patient-transport workers, medical examiners, nursing-home administrators, laboratory authorities, pharmacists, school authorities, daycare facilities, emergency medical service employees
- Confirmed or suspected cases must be reported within 24 hours

TB and HIPAA (45-CFR-164.512)

- 45 CFR 164.512 uses and disclosures for which consent, an authorization, or opportunity to agree or object is not required:
 - (b) Standard: uses and disclosures for public health activities

TB and HIPAA (45-CFR-164.512)

- -(1) Permitted disclosures
 - A covered entity may disclose protected health information for the public health activities and purposes describes in this paragraph to:

TB and HIPAA (45-CFR-164.512)


-(i) A public health authority that is authorized by law to collect or receive such information for the purpose of preventing or controlling disease, ... and the conduct of public health surveillance, public health investigations, and public health interventions; or, at the direction of a public health authority ...

TB Control

- The Division of TB Control has the responsibility to assure that training, education, and services are available for the identification, diagnosis, and treatment of tuberculosis
- Health care workers are encouraged to begin collaborative efforts with TB control staff in their area

TB Control

 Both immediate and long - term gains can be achieved as we work together to protect the public, our staff, and those in our care



A Global Perspective

- One third of the world's population is infected with TB
- Each year, 9 million people around the world become sick with TB
- Each year, there are over 2 million TB related deaths worldwide
- TB is the leading killer of people who are HIV infected
- 10,528 cases were reported in the United States in 2011

For More Information

Tammy Langlois, BSN, RN TB Nurse Consultant Division of TB Control Alabama Department of Public Health

334 - 206 - 5330

334 - 850 - 7970

Tammy.Langlois@adph.state.al.us